Spero Therapeutics

SPRO

Market cap $91.5M

SPRO Hedge Fund Activity: Q1 2026 in Review

50 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in Spero Therapeutics (SPRO) for Q1 2026, worth a combined $49.3M — up 0.15% from $49.2M a quarter earlier.

Sellers outnumbered buyers: 12 funds closed out of SPRO and 8 opened new positions — a net loss of 4 holders — while 10 trimmed existing stakes and 13 added.

The largest buyer was Two Sigma Investments, adding an estimated $1.22M. The largest seller was EAM Investors, exiting entirely with an estimated $508K sold.

• 50 institutional investors held Spero Therapeutics (SPRO) as of Q1 2026, down from 56 in Q4 2025.
• Funds reported $49.3M of Spero Therapeutics stock for Q1 2026, up 0.15% quarter-over-quarter.
• 8 funds opened new Spero Therapeutics positions in Q1 2026 and 12 closed out, a net change of -4 holders.
• The largest Spero Therapeutics buyer in Q1 2026 was Two Sigma Investments, an estimated $1.22M added.
• The largest Spero Therapeutics seller in Q1 2026 was EAM Investors, an estimated $508K sold.

Based on aggregated 13F filings for Q1 2026.